Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
| ▸ | LOX | P28300 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.43 |
| ▸ | ABAT | P80404 | 1/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577033 | 1.00 | MAPT (0.49) | MAPTIDH1LOXLOXL2ALDH1A1 | |
| SCHEMBL28426947 | 0.82 | XDH (0.49) | MAPTIDH1LOXLOXL2ALDH1A1 | |
| SCHEMBL17978127 | 0.82 | MAPT (0.41) | MAPTIDH1LOXLOXL2ALDH1A1 | |
| SCHEMBL6632692 | 0.82 | LOX (0.48) | MAPTIDH1LOXLOXL2ALDH1A1 | |
| SCHEMBL16179966 | 0.81 | CNR1 (0.48) | MAPTLOXLOXL2ALDH1A1TSHR | |
| SCHEMBL7399408 | 0.81 | ALDH1A1 (0.49) | MAPTALDH1A1TSHRFDPSTDP1 | |
| SCHEMBL28283107 | 0.80 | MAPT (0.72) | MAPTALDH1A1TSHRFDPSTDP1 | |
| SCHEMBL2092741 | 0.80 | LOX (0.47) | MAPTIDH1LOXLOXL2ALDH1A1 | |
| SCHEMBL7767987 | 0.80 | LOX (0.47) | MAPTIDH1LOXLOXL2ALDH1A1 | |
| SCHEMBL31588267 | 0.80 | LOX (0.47) | MAPTIDH1LOXLOXL2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | claimed |
| EP-3074385-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | Takeda Pharmaceutical Company Limited (JP) | 2016-10-05 | — | — | EP | claimed |
| WO-2015079224-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-06-04 | — | — | WO | claimed |
| EP-2797597-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | claimed |
| WO-2014145040-A1 | SUBSTITUTED ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| WO-2013102145-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | claimed |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026087634-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4073062-B1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2026-04-29 | — | — | EP | disclosed |
| EP-4727934-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-22 | — | — | EP | disclosed |
| EP-4720062-A1 | PYRIDO[3,4-D]PYRIMIDIN-4-ONE AND PYRIMIDO[5,4-D]PYRIMIDIN-4-ONE DERIVATIVES AS TREM2 AGONISTS FOR THE TREATMENT OF PARKINSON'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-4255428-A | ANTIINFLAMMATORY AGENTS, HISTAMINE BLOCKING AGENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-03-10 | — | — | US | disclosed |
| US-4234588-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-11-18 | — | — | US | disclosed |
| EP-0017680-A1 | Pyrimidone derivatives, process for preparing them and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-10-29 | — | — | EP | disclosed |
| US-4227000-A | Intermediates in the process for making histamine antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-10-07 | — | — | US | disclosed |
| EP-0007232-A1 | Iso(thio)ureas, processes for their preparation and compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-01-23 | — | — | EP | disclosed |
| EP-0004793-A2 | 2-nitro aminopyrimidone derivatives, a process for their preparation and their use to prepare 2-aminopyrimidone derivatives which have histamine H2-antagonist activity | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-10-17 | — | — | EP | disclosed |
| EP-0003677-A2 | Pyrimidones, processes for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ADRM1, CRBN, SNCA | MAPT 210/4885IDH1 1707/4885LOX 422/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | MAPT 2466/4885IDH1 187/4885LOX 1642/4885 |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM5, CHRM3 | MAPT 2127/4885IDH1 2506/4885LOX 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.